Astrazeneca (AZN) Receivables (2015 - 2025)

Astrazeneca (AZN) has reported Receivables for 18 consecutive years, with $14.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables rose 6.46% year-over-year to $14.1 billion; the TTM figure through Mar 2026 stood at $14.1 billion (up 6.46% YoY), while the FY2025 annual figure was $17.2 billion, up 18.16% from the prior year.
• Receivables came in at $14.1 billion for Q1 2026 at Astrazeneca, down from $17.2 billion in the prior quarter.
• The five-year high for Receivables was $17.2 billion in Q4 2025, with the low at $8.7 billion in Q1 2022.
• Average Receivables over 5 years is $12.0 billion, with a median of $11.3 billion recorded in 2023.
• Across the five-year window, Receivables jumped 74.97% in 2022 and decreased 17.52% in 2023, its largest moves.
• Year by year, Receivables stood at $12.2 billion in 2022, then fell by 17.52% to $10.0 billion in 2023, then surged by 44.84% to $14.6 billion in 2024, then advanced by 18.16% to $17.2 billion in 2025, then dropped by 17.96% to $14.1 billion in 2026.
• According to Business Quant data, Receivables over the past three periods registered $14.1 billion, $17.2 billion, and $14.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.